Every 10-Q that Nuvalent, Inc. (NUVL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUVL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVL filings page.
Nuvalent, Inc. reported a net loss of $109.3 million for the quarter ended March 31, 2026, wider than the $84.6 million loss a year earlier, as it accelerated R&D and commercial preparation. Research and development expenses rose to $83.6 million, while general and administrative costs increased to $35.8 million, reflecting higher headcount, stock-based compensation and launch planning.
The company remains pre-revenue and focused on oncology programs led by zidesamtinib, neladalkib and NVL‑330. It ended the quarter with $1.3 billion in cash, cash equivalents and marketable securities and believes this will fund operations into 2029, despite an accumulated deficit of about $1.1 billion.
Nuvalent, Inc. (NUVL) reported a larger quarterly loss while advancing its oncology pipeline. For Q3 2025, net loss was $122.4 million versus $84.3 million a year ago as operating expenses rose with clinical activity. Research and development reached $83.8 million (from $60.6 million) and general and administrative was $28.9 million (from $15.8 million).
Liquidity remains strong with cash, cash equivalents and marketable securities of $943.1 million as of September 30, 2025. The company reported an accumulated deficit of $853.7 million and noted its resources are expected to fund operations into 2028. The fair value of a related party revenue share liability increased to $45.2 million from $17.9 million, reflecting updated assumptions.
Program updates included completion of a rolling NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC and ongoing Phase 2 work in TKI-naïve patients. Neladalkib advanced with Phase 2 enrollment completed in TKI pre-treated NSCLC and initiation of the Phase 3 ALKAZAR trial in TKI‑naïve ALK‑positive NSCLC. NVL‑330 progressed in Phase 1 with new preclinical data highlighting brain‑penetrant properties.